NDA 020648 · Bausch
Diastat Acudial
Diazepam · Rectal · Benzodiazepine
OrphanLast checked: Nov 19, 2026Latest source record: Jul 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Jul 29, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
118
16 Phase 3, 6 recruiting
FAERS reports
90,054
76,639 serious, 20,859 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including diazepam rectal gel, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...
What it is approved for
From the label in effect Jan 4, 2024.
INDICATIONS AND USAGE Diazepam rectal gel is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 1997 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
7 products under this application
- DIASTAT ACUDIAL · DIAZEPAM 20MG/4ML (5MG/ML) · GEL, RECTAL · Prescription · TE AB
- DIASTAT · DIAZEPAM 15MG/3ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
- DIASTAT · DIAZEPAM 5MG/ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
- DIASTAT ACUDIAL · DIAZEPAM 10MG/2ML (5MG/ML) · GEL, RECTAL · Prescription · TE AB
- DIASTAT · DIAZEPAM 20MG/4ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
- DIASTAT · DIAZEPAM 10MG/2ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
- DIASTAT · DIAZEPAM 2.5MG/0.5ML (5MG/ML) · GEL, RECTAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Diazepam" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral VertigoPivotal-lookingStatus unknown
University of MonastirAcademic, hospital or other
NCT06293989 · 1,000 participants (planned) · Start May 1, 2024 · Primary completion Dec 30, 2025
Drug: Diazepam 5mg; Diazepam 10 mg and 1 more · For: Vertigo, Peripheral
- Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in AsthmaPivotal-lookingCompleted
Oriel TherapeuticsIndustry
NCT02260492 · 879 participants · Start Sep 2014 · Primary completion May 2015
Drug: OT329 (combination of fluticasone propionate and salmeterol xinafoate); Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate) and 1 more · For: Asthma
Sites: Goodyear, Arizona; Tempe, Arizona; Anaheim, California · 47 sites in all
- Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)Pivotal-lookingCompleted
Avanti AnesthesiaAcademic, hospital or other
NCT03653520 · 651 participants · Start Jun 28, 2017 · Primary completion Nov 2, 2017
Drug: Diazepam; Tramadol and 2 more · For: Cataract
Sites: Houston, Texas
- Therapeutic Drug Monitoring of Anxiolytics in ChildrenStatus unknown
Wei ZhaoAcademic, hospital or other
NCT03960671 · 500 participants (planned) · Start Aug 1, 2018 · Primary completion Dec 31, 2022
Drug: Midazolam/diazepam/propofol · For: Anxiolytics
Sites: Ji'nan, China
- Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)Pivotal-lookingCompleted
McMaster UniversityAcademic, hospital or other
NCT03053869 · 480 participants · Start Apr 1, 2017 · Primary completion Sep 30, 2018
Drug: Benzodiazepine - limited use strategy; Benzodiazepine - Ad libitum strategy · For: Post-operative Delirium
Sites: Winnipeg, Canada; Hamilton, Canada
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Diazepam at the Active Phase of LaborPivotal-lookingStatus unknown
Navy General Hospital, BeijingAcademic, hospital or other
NCT02232035 · 400 participants (planned) · Start Sep 2014 · Primary completion Sep 2015
Drug: normal saline/diazepam at the active phase of labor · For: Pain; Prolonged Labour
Sites: Beijing, China
- Intranasal Midazolam Versus Rectal Diazepam for Treatment of SeizuresPivotal-lookingCompleted
University of UtahAcademic, hospital or other
NCT00326612 · 358 participants · Start Jun 2006 · Primary completion Dec 2008
Drug: Midazolam; Diazepam · For: Seizures
Sites: Salt Lake City, Utah
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxicity to various agents9,224
- drug abuse6,198
- drug ineffective5,045
- nausea4,204
- drug interaction3,886
- completed suicide3,880
- fatigue3,807
- somnolence3,636
- off label use3,550
- anxiety3,387
- death3,387
- headache3,270
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,140 |
| 2005 | 1,344 |
| 2006 | 1,170 |
| 2007 | 1,233 |
| 2008 | 1,797 |
| 2009 | 1,793 |
| 2010 | 2,345 |
| 2011 | 2,776 |
| 2012 | 3,252 |
| 2013 | 3,740 |
| 2014 | 3,766 |
| 2015 | 4,657 |
| 2016 | 5,306 |
| 2017 | 5,529 |
| 2018 | 6,524 |
| 2019 | 7,145 |
| 2020 | 6,726 |
| 2021 | 5,695 |
| 2022 | 4,983 |
| 2023 | 4,864 |
| 2024 | 5,151 |
| 2025 | 5,144 |
| 2026 | 3,963 |
Recalls
1 FDA enforcement reports for this application.
Jul 10, 2018 · Class III · Terminated
Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.
Appleton R, Macleod S, Martland T · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Intermittent oral diazepam prophylaxis in febrile convulsions: its effectiveness for febrile seizure recurrence.
Verrotti A, Latini G, di Corcia G, et al. · Eur J Paediatr Neurol 2004 · Clinical Trial, Randomized Controlled Trial
- Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials.
Brigo F, Bragazzi NL, Bacigaluppi S, et al. · Epilepsy Behav 2016 · Meta-Analysis, Systematic Review
- Positive Allosteric Modulator of GABA Lowers BOLD Responses in the Cingulate Cortex.
Walter SA, Forsgren M, Lundengård K, et al. · PLoS One 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Concordance and incongruence in preclinical anxiety models: Systematic review and meta-analyses.
Mohammad F, Ho J, Woo JH, et al. · Neurosci Biobehav Rev 2016 · Meta-Analysis, Systematic Review
- Diazepam treatment of early signs of exacerbation in schizophrenia.
Carpenter WT, Buchanan RW, Kirkpatrick B, et al. · Am J Psychiatry 1999 · Clinical Trial, Comparative Study
Sponsor: Bausch · Also marketed as Diastat
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.